The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients
| Autor: | Ali Veral, Tulin Aysan, Duygu Ozol, Nesrin Mogulkoc, Zeynep Aytemur Solak, Filiz Sebik |
|---|---|
| Přispěvatelé: | Ege Üniversitesi |
| Jazyk: | angličtina |
| Rok vydání: | 2005 |
| Předmět: |
Pulmonary and Respiratory Medicine
Spirometry Budesonide Male medicine.medical_specialty Time Factors budesonide medicine.drug_class Placebo Gastroenterology Statistics Nonparametric Pulmonary Disease Chronic Obstructive Double-Blind Method Internal medicine Administration Inhalation medicine Humans COPD bronchoalveolar lavage inhaled Lymphocyte Count Glucocorticoids Aged Lung medicine.diagnostic_test Inhalation business.industry interleukin-8 Middle Aged medicine.disease Bronchodilator Agents respiratory tract diseases Bronchoalveolar lavage medicine.anatomical_structure Immunology Corticosteroid Female business Bronchoalveolar Lavage Fluid Biomarkers medicine.drug steroids |
| Popis: | WOS: 000234008000003 PubMed ID: 15946834 Chronic obstructive pulmonary disease (COPD) is characterised by a chronic inflammatory process in the large and small airways, as well as in the lung parenchyma. Although the rote of oral corticosteroids in the management of acute exacerbations of COPD is well documented, its rote in stable COPD is not clear. We examined the anti-inflammatory effect of inhaled budesonide on the percentage of neutrophils and on interleukin-8 (IL-8) levels in bronchoalveolar lavage (BAL) and their correlation with spirometry and symptom scores. Twenty-six patients with stable COPD were randomised, in a double-blinded, placebo-controlled trial with either 800 mu g of inhaled budesonide or placebo for a 6-month period. The budesonide-treated subjects had significant reductions in IL-8 levels in the BAL after therapy (mean +/- SEM, 1.53 +/- 0.72 at baseline vs. 0.70 +/- 0.48 ng/ml at 6 months, P = 0.004) and a reduction in the mean percentages of neutrophils (17.16 +/- 2.67% vs. 13.25 +/- 2.28% P = 0.002). The improvement in sputum production was of borderline (P = 0.058) significance but there was no improvement in lung function. In stable patients with COPD, treatment with inhaled budesonide for a period of 6 months has a positive effect on markers of lung inflammation, as assessed by reduction in percentage neutrophils and IL-8 concentration in BAL. (c) 2005 Elsevier Ltd. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|